Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia

• Published in: Journal of endocrinological investigation 2023-11, Vol.46 (11), p.2275-2286
• Main Authors: Jimenez-Canizales, C. E., Rojas, W., Alonso, D., Romero, I., Tabares, S., Veronesi Zuluaga, L. A., Modica, R., Colao, A.
• Format: Article
• Language: English
• Subjects: Adenoma; Biochemical characteristics; Brain tumors; Complications; Endocrinology; Hypopituitarism; Immunohistochemistry; Internal Medicine; Medical records; Medicine; Medicine & Public Health; Metabolic Diseases; Neuroendocrine tumors; Original Article; Patients; Pituitary; Postoperative; Remission
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-023-02080-w

Introduction Pituitary neuroendocrine tumors (PitNETs) represent 15–18.2% of all intracranial tumors. Their clinical presentation can range from chronic headache, visual defects, hypopituitarism to hormone excess syndromes. PitNETS are commonly classified as functioning neuroendocrine tumors (F-PitNETs) and non-functioning neuroendocrine tumors (NF-PitNETs). At the moment, new classification has emerged based on cell lineages. Almost 50% of all patients with PitNETs require surgical intervention, and about 25% of these have residual and persistent disease that may require additional management. Subjects and methods A retrospective cohort of medical records of patients with PitNETs, aiming to describe the incidence of recurrence of patients who received surgical treatment over a 12 month follow up period at San Jose Hospital (SJH) in Bogotá, Colombia, over an observation period of 10 years. Furthermore, clinical presentation, biochemical characteristics and immunohistochemistry, postoperative complications are detailed. Results Eight hundred and eighty-seven patients with pituitary tumors were included in the cohort; 83% (737/887) had a diagnosis of PitNET. Of these, 18.9% (140) received surgical management. The majority 58% (98/140) had nonfunctional-PitNETs (NF-PitNETs), followed by growth-hormone-secreting pituitary adenoma (22.1%; 33/140), adrenocorticotropic- hormone-secreting pituitary adenoma (9.3%; 13/140), and prolactinomas (9.3%; 13/140). A recurrence was found in 45.71% (64/140), subclassified as biochemical in 15.71% (22/140), controlled with medications in 20% (28/140), and remission occurred in 18.57% (26/140). Conclusion Clinical presentation and incidence of recurrence in patients with PitNETs in a referral center in Colombia are similar to other surgical cohorts with low cure rates and high recurrence.